首站-论文投稿智能助手
典型文献
Treatment-related adverse events of combined anti-angiogenic and immune checkpoint inhibitors: systematic review and meta-analysis
文献摘要:
Objective Immune checkpoint inhibitor (ICI) plus angiogenesis inhibitor (AI) combination therapy is anovel treatment model for multiple cancers that normalizes vascular-immune crosstalk to potentiate cancer immunity. In this review, we summarize the characteristics of adverse effects (AEs) and all fatal cases reported in clinical studies involing ICI + AI therapy. Methods Four databases were systematically searched for eligible studies, and 28 relevant studies were selected for inclusion. Results Of the patients included, 58.1% developed grade ≥ 3 AEs. The most common fatal AEs were cardiovascular events, severe infections, and hemorrhage. Compared with AI alone, ICI + AI therapy resulted in more cases of grade ≥ 3 proteinuria, liver injury, and fatal AEs (2.49% vs. 1.28%, P = 0.0041), especially respiratory toxicities and severe infections; however, ICI + AI therapy reduced hematological toxicity. Conclusion We shared comprehensive and practical safety data to review the adverse events associated with ICI + AI treatment.
文献关键词:
作者姓名:
Lian Chen;Ling Wu;Zhang Lu;Qin Huang;Liu Huang
作者机构:
Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China
引用格式:
[1]Lian Chen;Ling Wu;Zhang Lu;Qin Huang;Liu Huang-.Treatment-related adverse events of combined anti-angiogenic and immune checkpoint inhibitors: systematic review and meta-analysis)[J].肿瘤学与转化医学(英文),2022(06):301-310
A类:
anovel,involing
B类:
Treatment,related,adverse,events,combined,anti,angiogenic,immune,checkpoint,inhibitors,review,meta,analysis,Objective,Immune,ICI,plus,angiogenesis,combination,therapy,treatment,model,multiple,cancers,that,normalizes,crosstalk,potentiate,immunity,In,this,summarize,characteristics,effects,AEs,fatal,cases,reported,clinical,studies,Methods,Four,databases,were,systematically,searched,eligible,relevant,selected,inclusion,Results,Of,patients,included,developed,grade,most,common,cardiovascular,severe,infections,hemorrhage,Compared,alone,resulted,more,proteinuria,liver,injury,especially,respiratory,toxicities,however,reduced,hematological,toxicity,Conclusion,We,shared,comprehensive,practical,safety,associated
AB值:
0.606392
相似文献
Knowledge about,attitude and acceptance towards,and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China:A cross-sectional survey
Jing Hong;Xiao-wan Xu;Jing Yang;Jing Zheng;Shu-mei Dai;Ju Zhou;Qing-mei Zhang;Yi Ruan;Chang-quan Ling-School of Traditional Chinese Medicine,Naval Medical University,Shanghai 200433,China;Department of Integrative Oncology,Changhai Hospital,Naval Medical University,Shanghai 200433,China;Department of Oncology,The First Affiliated Hospital,Bengbu Medical College,Bengbu 233010,Anhui Province,China;Department of Nursing,Fuyang Cancer Hospital,Fuyang 236000,Anhui Province,China;Department of Cardiac Rehabilitation,Shanghai First Rehabilitation Hospital,Shanghai 200090,China;Department of Radiation Oncology,Anhui Chest Hospital,Hefei 230022,Anhui Province,China;Department of Anesthesiology,Chaohu Hospital,Anhui Medical University,Hefei 238000,Anhui Province,China
Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression?A systematic review and meta-analysis
Ming-min Xu;Pei Guo;Qing-yu Ma;Xuan Zhou;Yu-long Wei;Lu Wang;Yue Chen;Yu Guo-School of Traditional Chinese Medicine,Jinan University,Guangzhou 510632,Guangdong Province,China;Acupuncture and Tuina School/Third Teaching Hospital,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;School of Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;Guangzhou Key Laboratory of Formula-Pattern of Traditional Chinese Medicine,Formula-Pattern Research Center,Jinan University,Guangzhou 510632,Guangdong Province,China;School of Acupuncture-Moxibustion and Tuina,Beijing University of Chinese Medicine,Beijing 100029,China
Safety of acupotomy in a real-world setting:A prospective pilot and feasibility study
Sang-Hoon Yoon;Chan-Young Kwon;Hee-Geun Jo;Jae-Uk Sul;Hyangsook Lee;Jiyoon Won;Su Jin Jeong;Jun-Hwan Lee;Jungtae Leem-Chung-Yeon Korean Medicine Clinic,Gangnam-gu,Seoul 06224,Republic of Korea;Department of Oriental Neuropsychiatry,Dong-eui University College of Korean Medicine,Busanjin-gu,Busan 47340,Republic of Korea;Department of Herbal Pharmacology,College of Korean Medicine,Gachon University,1342 Seongnamdae-ro,Sujeong-gu,Seongnam 13120,Republic of Korea;Department of Korean Rehabilitation Medicine,Dongshin University Korean Medicine Hospital,Gwangju 61619,Republic of Korea;Acupuncture and Meridian Science Research Center,Kyung Hee University,Dongdaemun-gu,Seoul 02447,Republic of Korea;Department of Science in Korean Medicine,Graduate School,Kyung Hee University,Dongdaemun-gu,Seoul 02447,Republic of Kore;KM Science Research Division,Korea Institute of Oriental Medicine,Daejeon 34054,Republic of Korea;Department of Statistics Support,Medical Science Research Institute,Kyung Hee University Medical Center,Dongdaemun-gu,Seoul 02447,Republic of Korea;Clinical Medicine Division,Korea Institute of Oriental Medicine,Yuseong-gu,Daejeon 34054,Republic of Korea;Korean Medicine Life Science,University of Science&Technology(UST),Campus of Korea Institute of Oriental Medicine,Yuseong-gu,Daejeon 34054,Republic of Korea;College of Korean Medicine,Wonkwang University,Iksan,Jeollabuk-do 54538,Republic of Korea
Does reconstruction affect outcomes following exclusively endoscopic endonasal resection of benign orbital tumors: A systematic review with meta-analysis
Lehmann Ashton E.;von Sneidern Manuela;Shen Sarek A.;Humphreys Ian M.;Abuzeid Waleed M.;Jafari Aria-Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA;Department of Otolaryngology-Head and Neck Surgery, Geisinger Medical Center, Danville, Pennsylvania, USA;Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, USA;Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA;Division of Rhinology and Endoscopic Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China
Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅱ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou 310020,China;Department of Oncology,Baotou Cancer Hospital,Baotou 014030,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
Anlotinib as third-or further-line therapy for short-term relapsed small-cell lung cancer:subgroup analysis of a randomized phase 2 study(ALTER1202)
Jianhua Shi;Ying Cheng;Qiming Wang;Kai Li;Lin Wu;Baohui Han;Gongyan Chen;Jianxing He;Jie Wang;Haifeng Qin;Xiaoling Li-Department of Medical Oncology,Linyi Cancer Hospital,Linyi 276002,China;Department of Thoracic Medical Oncology,Jilin Cancer Hospital,Changchun 130012,China;Department of Internal Medicine,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450003,China;Department of Pulmonary Oncology,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Department of Thoracic Medical Oncology,The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University(Hunan Cancer Hospital),Changsha 410031,China;Department of Respiratory Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Respiratory Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Thoracic Surgery,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Pulmonary Oncology,The Fifth Medical Centre of Chinese PLA General Hospital,Beijing 100039,China;Department of Medical Oncology,Liaoning Cancer Hospital,Shenyang 110042,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。